These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 27163398)

  • 1. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis.
    Gasparini R; Landa P; Amicizia D; Icardi G; Ricciardi W; de Waure C; Tanfani E; Bonanni P; Lucioni C; Testi A; Panatto D
    Hum Vaccin Immunother; 2016 Aug; 12(8):2148-2161. PubMed ID: 27163398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.
    Pouwels KB; Hak E; van der Ende A; Christensen H; van den Dobbelsteen GP; Postma MJ
    Hum Vaccin Immunother; 2013 May; 9(5):1129-38. PubMed ID: 23406816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
    Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
    Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(®) to reduce meningococcal group B disease in Germany.
    Christensen H; Irving T; Koch J; Trotter CL; Ultsch B; Weidemann F; Wichmann O; Hellenbrand W
    Vaccine; 2016 Jun; 34(29):3412-9. PubMed ID: 27109566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
    Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bexsero, a novel vaccine against meningococcus].
    Lakos A; Torzsa P; Ferenci T
    Orv Hetil; 2016 Feb; 157(7):242-6. PubMed ID: 26853725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
    Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
    Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.
    Izquierdo G; Torres JP; Santolaya ME; Valenzuela MT; Vega J; Chomali M
    Hum Vaccin Immunother; 2015; 11(4):875-83. PubMed ID: 25714390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme--New challenges for public health.
    Ladhani SN; Campbell H; Parikh SR; Saliba V; Borrow R; Ramsay M
    J Infect; 2015 Dec; 71(6):611-4. PubMed ID: 26433141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme.
    Tirani M; Meregaglia M; Melegaro A
    PLoS One; 2015; 10(4):e0123383. PubMed ID: 25874805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact.
    Christensen H; Hickman M; Edmunds WJ; Trotter CL
    Vaccine; 2013 May; 31(23):2638-46. PubMed ID: 23566946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease.
    Beck E; Klint J; Neine M; Garcia S; Meszaros K
    Value Health; 2021 Jan; 24(1):91-104. PubMed ID: 33431159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation on meningococcal vaccination strategies among children under nine years of age in Zhejiang province, China.
    Shen J; Ji C; Luo X; Hu Y
    PLoS One; 2024; 19(9):e0310274. PubMed ID: 39250492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meningococcal vaccines: Current state and future outlook.
    Leca M; Bornet C; Montana M; Curti C; Vanelle P
    Pathol Biol (Paris); 2015 Jun; 63(3):144-51. PubMed ID: 25986879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination.
    Carter NJ
    BioDrugs; 2013 Jun; 27(3):263-74. PubMed ID: 23575646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health impact and cost-effectiveness of introducing the vaccine (Bexsero) against MenB disease into the Brazilian immunization programme.
    Moura Silveira M; McBride AJA; Trotter CL
    Vaccine; 2019 Oct; 37(45):6783-6786. PubMed ID: 31570182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with the meningococcal B vaccine, Bexsero(®): Prospects for reducing the burden of meningococcal serogroup B disease.
    Watson PS; Turner DP
    Vaccine; 2016 Feb; 34(7):875-80. PubMed ID: 26686570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.
    Esposito S; Principi N
    Expert Rev Vaccines; 2014 Feb; 13(2):193-202. PubMed ID: 24393061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults.
    Leeds IL; Namasivayam V; Bamogo A; Sankhla P; Thayer WM
    Am J Prev Med; 2019 Feb; 56(2):196-204. PubMed ID: 30573332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.